These 5 Chicago Tech Companies Raised the Most Funding in November
Several local tech companies are looking to close out the year strong with fresh capital and plans to hire. Last month, Chicago-based companies ranging from bioscience to logistics raised new capital. The five largest funding rounds totaled a combined $380 million in November.
Largest Chicago Tech Funding Rounds, November 2022
- Emalex Biosciences
- Better Trucks
#5. Logwia: $10 million, November 3
Logiwa is a logistics software platform that helps direct-to-consumer brands improve their warehouse order processing. Last month, the Chicago-based company raised $10 million in a Series B round co-led by Prologis Ventures and BAM Elevate. With the fresh funding, Logiwa plans to accelerate the development of its software.
#4. Better Trucks: $15 million, November 15
In November, Better Trucks raised $15 million in a round led by Lobby Capital. Better Trucks is a last-mile delivery carrier that offers retailers next-day and two-day shipping services. With the new capital, Better Trucks will acquire more warehouse space across the country in order to provide its services to more brands. The company said it will also launch hiring initiatives in the near future.
#3. Attain: $25 million, November 1
In early November, data insights platform Klover rebranded to Attain and raised $25 million in a Series B round. With the new capital, the company will release new consumer-facing apps that provide data. To leverage the funding, Attain is also currently hiring and has several openings listed on Built In.
#2. Project44: $80 million, November 3
Project44 is a logistics company that works with automotive, retail, food and beverage companies. Last month, project44 raised $80 million, bringing its valuation to $2.7 billion. With the new funding, the company will develop a new supply chain platform that tracks carbon emissions for its customers.
#1. Emalex Biosciences: $250 million, November 3
Emalex Biosciences, a pharmaceutical company, raised the most local capital in November with a $250 million Series D round. The company said it will use its new funding to conduct clinical trials on a new drug for Tourette Syndrome, a condition of the nervous system that causes people to make sudden and repetitive twitches, movements or sounds.